Raza, A., Galili, N., Mulford, D., Smith, S. E., Brown, G. L., Steensma, D. P., . . . Mesa, R. A. (2012). Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). BioMed Central.
Citação norma ChicagoRaza, Azra, et al. Phase 1 Dose-ranging Study of Ezatiostat Hydrochloride in Combination With Lenalidomide in Patients With Non-deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). BioMed Central, 2012.
MLA CitationRaza, Azra, et al. Phase 1 Dose-ranging Study of Ezatiostat Hydrochloride in Combination With Lenalidomide in Patients With Non-deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). BioMed Central, 2012.